Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants

Vaccine

Volumn 26, Issue 52, 2008, Pages 6824-6831

  White, P J ^a   Anastasopoulos, F ^a   Church, J E ^a   Kuo, C Y ^a   Boyd, B J ^a   Hickey, P L C ^b   Tu, L Sze ^b   Burns, P ^b   Lew, A M ^c   Heath, W R ^c   Davey, G M ^c   Pouton, C W ^a  

^a MONASH UNIVERSITY   (Australia)

^b Eiffel Technologies Limited   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Dense gas processing; Ovalbumin; Pure protein particle; Vaccine

Indexed keywords

OVALBUMIN; PROTEIN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PH; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PROCESSING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CHICKENS; IMMUNITY, CELLULAR; IMMUNIZATION; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, SCANNING; MURAMIDASE; OVALBUMIN; PARTICLE SIZE; PARTICULATE MATTER; T-LYMPHOCYTES; VACCINES;

EID: 56949105659     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.087     Document Type: Article

References (36)

1. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci August (2007)
2. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 January (4) (2008) 552-561
3. Singh M., Fang J.H., Kazzaz J., Ugozzoli M., Chesko J., Malyala P., et al. A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. Int J Pharm 327 December (1-2) (2006) 1-5
4. Singh M., Kazzaz J., Ugozzoli M., Malyala P., Chesko J., and O'Hagan D.T. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv 3 January (1) (2006) 115-120
5. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 40 September (1) (2006) 1-9
6. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly({gamma}-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 178 March (5) (2007) 2979-2986
7. Denis J., Majeau N., Acosta-Ramirez E., Savard C., Bedard M.C., Simard S., et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 363 June (1) (2007) 59-68
8. Pessi A., Valmori D., Migliorini P., Tougne C., Bianchi E., Lambert P.H., et al. Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide. Eur J Immunol 21 September (9) (1991) 2273-2276
9. Rosenberg A.S. Effects of protein aggregates: an immunologic perspective. Aaps J 8 3 (2006) E501-E507
10. Tam J.P., and Lu Y.A. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes. Proc Natl Acad Sci USA 86 December (23) (1989) 9084-9088
11. Dresser D.W., and Mitchison N.A. The mechanism of immunological paralysis. Adv Immunol 8 (1968) 129-181
12. Ludwig C., and Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 18 December (6) (2007) 537-545
13. Ke Y., Li Y., and Kapp J.A. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur J Immunol 25 February (2) (1995) 549-553
14. Harding C.V., and Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 153 December (11) (1994) 4925-4933
15. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 September (5) (2004) 3148-3154
16. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117 January (1) (2006) 78-88
17. Klein J. Probing the interactions of proteins and nanoparticles. Proc Natl Acad Sci USA 104 February (7) (2007) 2029-2030
18. Winters M.A., Knutson B.L., Debenedetti P.G., Sparks H.G., Przybycien T.M., Stevenson C.L., et al. Precipitation of proteins in supercritical carbon dioxide. J Pharm Sci 85 June (6) (1996) 586-594
19. Yeo S.D., Debendetti P.G., Patro S.Y., and Przybycien T.M. Secondary structure characterization of microparticulate insulin powders. J Pharm Sci 83 December (12) (1994) 1651-1656
20. Uchida T., and Goto S. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study. Biol Pharm Bull 17 September (9) (1994) 1272-1276
21. Uchida T., Goto S., and Foster T.P. Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation. J Pharm Pharmacol 47 July (7) (1995) 556-560
22. Barnden M.J., Allison J., Heath W.R., and Carbone F.R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76 February (1) (1998) 34-40
23. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., and Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 76 January (1) (1994) 17-27
24. Burger J.L., Cape S.P., Braun C.S., McAdams D.H., Best J.A., Bhagwat P., et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 21 March (1) (2008) 25-34
25. Sievers R., Quinn B.P., Cape S.P., Searles J.A., Braun C.S., Bhagwata P., et al. Near-critical fluid micronization of stabilized vaccines, antibiotics and anti-virals. J Supercrit Fluids 42 3 (2007) 385-391
26. Winters M.A., Debenedetti P.G., Carey J., Sparks H.G., Sane S.U., and Przybycien T.M. Long-term and high-temperature storage of supercritically-processed microparticulate protein powders. Pharm Res 14 October (10) (1997) 1370-1378
27. Liu H.L., Hsieh W.C., and Liu H.S. Molecular dynamics simulations to determine the effect of supercritical carbon dioxide on the structural integrity of hen egg white lysozyme. Biotechnol Prog 20 May-June (3) (2004) 930-938
28. Hutchings C.L., Gilbert S.C., Hill A.V., and Moore A.C. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175 July (1) (2005) 599-606
29. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., Wu C.Y., Wille U., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171 September (5) (2003) 2538-2547
30. Speidel K., Osen W., Faath S., Hilgert I., Obst R., Braspenning J., et al. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 27 September (9) (1997) 2391-2399
31. Li M., Davey G.M., Sutherland R.M., Kurts C., Lew A.M., Hirst C., et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 166 May (10) (2001) 6099-6103
32. Kalkanidis M., Pietersz G.A., Xiang S.D., Mottram P.L., Crimeen-Irwin B., Ardipradja K., et al. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods 40 September (1) (2006) 20-29
33. Jung T., Kamm W., Breitenbach A., Hungerer K.D., Hundt E., and Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 18 March (3) (2001) 352-360
34. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., and Pedraz J.L. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21 November (1-2) (2002) 67-77
35. Vila A., Sanchez A., Evora C., Soriano I., Vila Jato J.L., and Alonso M.J. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17 Summer (2) (2004) 174-185
36. Widera G., Johnson J., Kim L., Libiran L., Nyam K., Daddona P.E., et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24 March (10) (2006) 1653-1664